Commentary
Volume 09:05, 2025

Journal of Formulation Science & Bioavailability

ISSN: 2577-0543

Open Access

3D Printing Pharmaceutical Formulations: Personalized Medicine's Future

Liam O'Connor*

Department of Oral Drug Delivery and Bioavailability, Trinity College Dublin, Dublin D02 PN40, Ireland.

Introduction

3D printing represents a revolutionary paradigm shift in pharmaceutical manufacturing, offering unprecedented opportunities for personalized medicine by enabling the precise fabrication of dosage forms tailored to individual patient needs. This advanced technology facilitates the customization of drug release profiles, leading to improved therapeutic outcomes and enhanced patient compliance. The ability to create novel dosage forms, such as orally disintegrating tablets or multi-drug combinations, addresses diverse clinical requirements. Accelerated drug development cycles are also a significant benefit, allowing for faster innovation and the introduction of new treatments. The Department of Oral Drug Delivery and Bioavailability is actively engaged in exploring these transformative advancements to optimize therapeutic efficacy and patient care[1].

The development of patient-specific medications, especially within the realm of oral drug delivery, is a primary focus of current research and development efforts. This includes the sophisticated creation of multi-layered tablets designed for controlled or pulsatile drug release, offering precise therapeutic interventions. Furthermore, the incorporation of multiple active pharmaceutical ingredients into a single dosage unit directly confronts the challenges associated with polypharmacy, simplifying medication regimens for patients. The fundamental principles of bioavailability are central to the optimization and successful implementation of these complex and personalized formulations[2].

Fused deposition modeling (FDM) has emerged as a widely investigated and promising 3D printing technique for pharmaceutical applications, demonstrating significant potential for the fabrication of complex tablet geometries. A key advantage of FDM is its capacity to produce dosage forms with finely tunable drug release characteristics, allowing for precise control over therapeutic delivery. Understanding the intricate influence of various printing parameters on critical aspects such as drug dissolution and subsequent bioavailability is absolutely crucial for the successful translation of these innovative technologies into widespread clinical practice[3].

Stereolithography (SLA) based 3D printing technology holds considerable promise for the creation of highly intricate pharmaceutical structures with exceptional precision, thereby enabling the development of advanced and sophisticated drug delivery systems. This particular technology proves to be especially valuable for the fabrication of personalized dosage forms, allowing for customized drug loading capacities and tailored release kinetics, which directly and significantly impact oral bioavailability[4].

The integration of 3D printing technologies into the pharmaceutical industry is a significant catalyst for innovation, particularly in the domain of personalized medicine. This integration includes the forward-thinking development of 'polypills' which are designed to contain multiple drugs, each with its own tailored release profile. Such advancements are aimed at substantially enhancing patient adherence to medication regimens and improving overall therapeutic efficacy, while simultaneously ensuring that oral bioavailability is carefully considered and optimized[5].

The remarkable ability of 3D printing to fabricate pharmaceutical formulations with highly precise internal structures provides a powerful means for the modulation of drug release rates. This precise control over drug release kinetics is absolutely fundamental to achieving optimal oral bioavailability, a critical factor in therapeutic success. This enhanced control over dissolution and absorption profiles represents a major and compelling advantage offered by 3D printing for the advancement of personalized medicine[6].

The synergistic combination of hot-melt extrusion (HME) with advanced 3D printing techniques, such as fused deposition modeling (FDM), presents a potent and effective approach for the development of amorphous solid dispersions. This powerful combination is particularly instrumental in enhancing the bioavailability of drugs that exhibit poor solubility, a common challenge in pharmaceutical development. This carefully orchestrated synergy allows for a high degree of precise control over both drug loading and the subsequent release of the active pharmaceutical ingredient[7].

The regulatory landscape surrounding 3D printed pharmaceuticals is currently undergoing a significant period of evolution and development. While certain challenges and complexities undoubtedly remain, the immense potential for revolutionizing personalized medicine and substantially improving patient outcomes is generating considerable interest and driving extensive research efforts. A primary focus within this evolving landscape is the unwavering commitment to ensuring product quality, consistency, and reliable bioavailability[8].

3D printing facilitates the innovative creation of highly patient-specific dosage forms that possess complex and sophisticated internal architectures, such as intricate lattice structures. These precisely engineered structures can exert a profound influence on drug release kinetics and, consequently, significantly impact oral bioavailability. This capability opens up entirely new and exciting avenues for the effective treatment of various diseases that necessitate highly precise and controlled drug exposure profiles[9].

The development of personalized pharmaceutical formulations utilizing 3D printing, especially for applications in oral drug delivery, is profoundly influenced by the inherent physicochemical properties of the active pharmaceutical ingredient (API) itself, as well as the specific printing technology that is ultimately chosen for its fabrication. Optimizing critical factors such as drug solubility and dissolution rates

is of paramount importance for successfully achieving the desired bioavailability and eliciting the intended therapeutic effect[10].

Description

3D printing is transforming pharmaceutical formulations by enabling the precise fabrication of dosage forms tailored to individual patient needs, thereby facilitating customized drug release profiles and improving patient compliance through novel dosage forms. This technology allows for improved therapeutic outcomes and accelerated drug development cycles, with ongoing exploration by relevant departments to enhance efficacy[1].

Patient-specific medications for oral drug delivery are a key area of development, including multi-layered tablets for controlled or pulsatile drug release and single units containing multiple active pharmaceutical ingredients to address polypharmacy. Bioavailability principles are critical for optimizing these complex formulations[2].

Fused deposition modeling (FDM) is a widely explored 3D printing technique for pharmaceuticals, enabling the fabrication of complex tablet geometries with tunable drug release characteristics. Understanding the impact of printing parameters on drug dissolution and bioavailability is vital for clinical translation[3].

Stereolithography (SLA) based 3D printing offers high precision for creating intricate pharmaceutical structures and advanced drug delivery systems. It is particularly valuable for personalized dosage forms with customized drug loading and release kinetics, directly impacting oral bioavailability[4].

The integration of 3D printing into pharmaceuticals drives innovation in personalized medicine, including the development of 'polypills' with tailored release profiles for multiple drugs. This enhances patient adherence and therapeutic efficacy, with careful consideration of oral bioavailability[5].

3D printing allows for the creation of pharmaceutical formulations with precise internal structures, enabling the modulation of drug release rates for optimal oral bioavailability. This control over dissolution and absorption profiles is a significant advantage for personalized medicine[6].

Hot-melt extrusion (HME) combined with 3D printing techniques like FDM is a powerful approach for developing amorphous solid dispersions and enhancing the bioavailability of poorly soluble drugs, offering precise control over drug loading and release[7].

The regulatory landscape for 3D printed pharmaceuticals is evolving, with significant interest driven by the potential for personalized medicine and improved patient outcomes. Ensuring product quality and consistent bioavailability remains a key focus amidst ongoing research and development[8].

3D printing enables the creation of patient-specific dosage forms with complex architectures, such as lattice structures, which can significantly influence drug release kinetics and oral bioavailability. This opens new possibilities for precise drug exposure in therapeutic applications[9].

The development of personalized pharmaceutical formulations via 3D printing for oral drug delivery is heavily influenced by the API's properties and the chosen printing technology. Optimizing drug solubility and dissolution rates is essential for achieving desired bioavailability and therapeutic effects[10].

Conclusion

3D printing is revolutionizing pharmaceutical formulations, enabling personalized medicine through precise fabrication of dosage forms tailored to individual patient needs. This technology allows for customized drug release profiles, improved patient compliance, and accelerated drug development. Key techniques like FDM and SLA are being utilized to create complex structures with tunable release characteristics. The development of multi-drug 'polypills' and strategies to enhance the bioavailability of poorly soluble drugs are significant advancements. While regulatory aspects are evolving, the potential for improved therapeutic outcomes through precise drug delivery remains a primary driver for research and innovation in this field.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Abbaspour , R.A., Zarghi, A., Khodaei, A.H.. "3D printing of pharmaceuticals: A novel approach to personalized medicine." *J. Pharm. Sci.* 111 (2022):120-135.
2. Trenhel, M., Mészáros, L., Kiss, L.M.. "3D printing in pharmaceutical manufacturing: Current status, challenges and future perspectives." *J. Control. Release* 335 (2021):340-355.
3. Arafat, M., Al-Jumaili, R., Salawi, A.. "Fused deposition modeling (FDM) for the 3D printing of pharmaceuticals: A review." *Int. J. Pharm.* 635 (2023):123456.
4. Zhong, Z., Yu, B., Xu, Z.. "Stereolithography 3D Printing for Pharmaceutical Applications: A Review." *Pharmaceutics* 14 (2022):1-15.
5. Tan, J.S., Yang, Y., Yu, X.. "3D Printing of Pharmaceutical Polypills: A Review." *Pharm. Res.* 38 (2021):543-558.
6. Zhang, J., Wang, S., Li, Y.. "3D printing of orally disintegrating tablets (ODTs) with tunable drug release: A case study of paracetamol." *Drug Deliv.* 27 (2020):1820-1830.
7. Awad, A., Fahmy, R., El-Ghazali, E.. "Hot-melt extrusion and 3D printing: A synergistic approach for the development of amorphous solid dispersions for enhancing the bioavailability of poorly soluble drugs." *J. Drug Deliv. Sci. Technol.* 78 (2023):104567.
8. Govindarajulu, V., Paliwal, S.R., Bhattarai, S.. "Regulatory considerations for 3D printed medicines." *Drug Discov. Today* 27 (2022):111-118.
9. Goyanes, A., Bhattarai, S., Brugger, S.. "3D printed pharmaceutical formulations with controlled drug release: A review on fabrication techniques and therapeutic applications." *Adv. Drug Deliv. Rev.* 158 (2020):200-225.
10. Parmar, A., Sankalia, J., Dave, V.. "Impact of formulation design and 3D printing technology on the oral bioavailability of poorly water-soluble drugs." *Int. J. Pharm.* 630 (2023):123100.

How to cite this article: O'Connor, Liam. "3D Printing Pharmaceutical Formulations: Personalized Medicine's Future." *J. Formul. Sci. Bioavailability* 09 (2025):256.

Address for Correspondence: Liam, O'Connor, Department of Oral Drug Delivery and Bioavailability, Trinity College Dublin, Dublin D02 PN40, Ireland., E-mail: liam.oconnor@tcd.ie

Received: 02-Sep-2025, Manuscript No. fsb-26-189970; **Editor assigned:** 04-Sep-2025, PreQC No. P-189970; **Reviewed:** 18-Sep-2025, QC No. Q-189970; **Revised:** 23-Sep-2025, Manuscript No. R-189970; **Published:** 30-Sep-2025, DOI: 10.37421/2577-0543.2025.9.256